The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.

The interaction of thrombin with plasminogen activator inhibitor 1 (PAI-1) is shown to result in the simultaneous formation of both cleaved PAI-1 and a sodium dodecyl sulfate-stable thrombin-PAI-1 complex. The kinetics of this reaction can be described by a "suicide substrate" mechanism that includes a branched reaction pathway, which terminates in either the stable inhibitor-enzyme complex or the cleaved inhibitor plus free enzyme. Because of the branched pathway, approximately three moles of PAI-1 are needed to completely inhibit one mole of thrombin. Heparin and vitronectin enhance the rate of inhibition from 9.8 x 10(2) L mol(-1) s(-1) to 6.2 x 10(4) L mol(-1) s(-1) and 2.1 x 10(5) L mol(-1) s(-1), respectively, under optimal conditions. In addition to enhancing the rate of inhibition, both cofactors increase the apparent stoichiometry of the PAI-1-thrombin interaction, with cofactor concentration dependencies similar to the inhibition reaction. Thus, at 37 degrees C approximately six cleavage reactions occur per inhibition reaction. Therefore, thrombin will efficiently inactivate PAI-1 in the presence of either vitronectin or heparin, unless a sufficient excess of the inhibitor is present. These results show that physiological cofactors are able to switch a protease-serpin inhibition reaction to a substrate reaction, depending on the local concentrations of each of the components.

[1]  D. Lawrence,et al.  Plasminogen Activator Inhibitor-1 and Vitronectin Promote the Cellular Clearance of Thrombin by Low Density Lipoprotein Receptor-related Proteins 1 and 2 (*) , 1996, The Journal of Biological Chemistry.

[2]  A. V. van Zonneveld,et al.  Selective Screening of a Large Phage Display Library of Plasminogen Activator Inhibitor 1 Mutants to Localize Interaction Sites with Either Thrombin or the Variable Region 1 of Tissue-type Plasminogen Activator (*) , 1996, The Journal of Biological Chemistry.

[3]  L. Johansson,et al.  Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. , 1995, Biochemistry.

[4]  H. Pannekoek,et al.  Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update , 1995 .

[5]  G Pohl,et al.  Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. , 1994, Biochimica et biophysica acta.

[6]  P. Gettins,et al.  Serpins Are Suicide Substrates: Implications for the Regulation of Proteolytic Pathways , 1994, Seminars in thrombosis and hemostasis.

[7]  P. Patston,et al.  Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin , 1994 .

[8]  P. Declerck,et al.  Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. , 1994, The Journal of biological chemistry.

[9]  P. Hufnagl,et al.  Thrombin Stimulates Expression of Tissue-Type Plasminogen Activator and Plasminogen Activator lnhibitor Type 1 in Cultured Human Vascular Smooth Muscle Cells , 1993, Thrombosis and Haemostasis.

[10]  M. Nesheim,et al.  On the Existence of Platelet Receptors for Factor V(a) and Factor VIII(a) , 1993, Thrombosis and Haemostasis.

[11]  D. Lawrence,et al.  Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. , 1993, The Journal of biological chemistry.

[12]  H. Pannekoek,et al.  Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. , 1993, Biochemistry.

[13]  A. V. van Zonneveld,et al.  Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1. , 1993, The Journal of biological chemistry.

[14]  L. Johansson,et al.  A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. , 1992, European journal of biochemistry.

[15]  Thiennu H. Vu,et al.  Thrombin receptor expression in normal and atherosclerotic human arteries. , 1992, The Journal of clinical investigation.

[16]  S. Olson,et al.  Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. , 1992, The Journal of biological chemistry.

[17]  D. Vaughan,et al.  Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. , 1992, The Journal of biological chemistry.

[18]  S. Olson,et al.  Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor. , 1992, The Journal of biological chemistry.

[19]  K. Preissner,et al.  Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix , 1991, The Journal of cell biology.

[20]  J. Beechem,et al.  Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. , 1991, Biochemistry.

[21]  C. Esmon,et al.  Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Preissner,et al.  Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. , 1991, Biochemistry.

[23]  E. Goldsmith,et al.  Restoration of serine protease-inhibitor interaction by protein engineering. , 1990, The Journal of biological chemistry.

[24]  K. Griendling,et al.  Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and -independent pathways. , 1990, The Journal of biological chemistry.

[25]  K. Preissner,et al.  Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. , 1990, The Journal of biological chemistry.

[26]  E. Goldsmith,et al.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Goldsmith,et al.  Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.

[28]  E. Ruoslahti,et al.  Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. , 1989, The Journal of biological chemistry.

[29]  J. Mimuro,et al.  Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. , 1987, Blood.

[30]  F. Blasi,et al.  Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencing , 1986, FEBS letters.

[31]  R. Lebo,et al.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.

[32]  H. Lambers,et al.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. , 1986, The EMBO journal.

[33]  J. Millán,et al.  Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Dahlbäck,et al.  Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. , 1986, The Journal of biological chemistry.

[35]  K. Mann,et al.  Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin. , 1986, The Journal of biological chemistry.

[36]  S. Olson Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. , 1985, The Journal of biological chemistry.

[37]  S. Waley Kinetics of suicide substrates. Practical procedures for determining parameters. , 1985, The Biochemical journal.

[38]  J. Marcum,et al.  Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. , 1985, Biochemical and biophysical research communications.

[39]  M. Nesheim A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. , 1983, The Journal of biological chemistry.

[40]  G. Nelsestuen,et al.  The rate-determining step of the heparin-catalyzed antithrombin/thrombin reaction is independent of thrombin. , 1982, The Journal of biological chemistry.

[41]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[42]  S. G. Waley,et al.  Kinetics of suicide substrates. , 1980, The Biochemical journal.

[43]  K. Mann,et al.  Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. , 1979, Biochemistry.

[44]  E. Davie,et al.  A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. , 1977, Biochemistry.

[45]  B. Sobel,et al.  Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. , 1993, Circulation research.

[46]  C. Walsh Suicide substrates, mechanism-based enzyme inactivators: recent developments. , 1984, Annual review of biochemistry.

[47]  E. Shaw,et al.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. , 1979, Thrombosis research.